The Great Weight Debate: Unpacking the White House's Bold Move on Obesity Drugs

A Grand Bargain for Health? The Looming Question of Obesity Drugs and Who Pays.

The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The Great Negotiation: Big Pharma, Weight Loss, and the White House

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Billion-Dollar Standoff: Pfizer Takes On Novo Nordisk for a Slice of the Future

The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

A Major Turnaround: US Obesity Rates Witness Significant Decline in 2024

A Healthier Horizon: US Obesity Rates Show Promising Decline in 2024

Pfizer's Bold Gambit: Unleashing New Weapons in the Global Battle Against Obesity

The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?